Roche signs nearly $1B degrader pact with China's Defand
Roche has formed its fourth partnership in China since August, this time with Defand. The agreement could reach nearly $1 billion if all milestones are achieved. Defand is a Hangzhou-based startup focused on protein degraders.
Roche has now formed its fourth collaboration in China since August, with Defand as the newest partner. The agreement’s value could approach $1 billion if every milestone is met.
Defand is a startup based in Hangzhou and works on protein degraders. The pact adds to Roche’s recent China-facing dealmaking, while the final payout remains contingent on future progress.
If the partnership progresses, patients could eventually gain new treatment options from protein-degrader research, though timelines and outcomes remain uncertain. Roche’s repeated China collaborations may strengthen cross-border drug development ties, potentially affecting researchers, investors, and health systems. The milestone-based structure could shape how risk and reward are shared, but societal benefit would depend on whether the science becomes safe, effective medicine.